<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03695185</url>
  </required_header>
  <id_info>
    <org_study_id>M15-722</org_study_id>
    <secondary_id>2018-000930-37</secondary_id>
    <nct_id>NCT03695185</nct_id>
  </id_info>
  <brief_title>A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy</brief_title>
  <official_title>A Multicenter, Single Arm, Open-label Study to Investigate the Efficacy and Safety of Ravagalimab (ABBV-323) in Subjects With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study M15-722 is a Phase 2a study to investigate the efficacy and safety of Ravagalimab
      (ABBV-323) in participants with moderate to severe UC who failed prior therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 26, 2019</start_date>
  <completion_date type="Anticipated">August 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 18, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Endoscopic Improvement</measure>
    <time_frame>At Week 8</time_frame>
    <description>Endoscopic Improvement is defined as Mayo endoscopic subscore of 0 or 1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Clinical Remission per Adapted Mayo Score</measure>
    <time_frame>At Week 8</time_frame>
    <description>Clinical remission per Adapted Mayo score is defined as stool frequency subscore (SFS) &lt;=1, and not greater than baseline, rectal bleeding subscore (RBS) = 0 , and endoscopic subscore &lt;=1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Clinical Response per Adapted Mayo Score</measure>
    <time_frame>At Week 8</time_frame>
    <description>Clinical response per Adapted Mayo score is defined as the decrease from Baseline &gt;= 2 points and &gt;= 30%, PLUS a decrease in RBS &gt;=1 or an absolute RBS &lt;=1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Clinical Response per Partial Adapted Mayo Score</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>Clinical response per Partial Adapted Mayo score is defined as decrease from baseline &gt;=1 points and &gt;=30%, PLUS a decrease in RBS &gt;= 1 or an absolute RBS &lt;=1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Clinical Remission per Full Mayo Score in Participants with a Full Mayo Score of 6 to 12 at Baseline</measure>
    <time_frame>At Week 8</time_frame>
    <description>Clinical Remission per full Mayo score is defined as Full Mayo score &lt;=2 with no subscore &gt; 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Endoscopic Remission</measure>
    <time_frame>At Week 8</time_frame>
    <description>Endoscopic remission is defined as Mayo endoscopic subscore = 0.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Ulcerative Colitis (UC)</condition>
  <arm_group>
    <arm_group_label>ABBV-323</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants administered with ABBV-323 dose A IV at Week 0 and ABBV-323 dose B for 12 Weeks. Participants who achieve clinical response may enter the maintenance period in which participants are administered with ABBV-323 dose B</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABBV-323 Dose A</intervention_name>
    <description>ABBV-323 Dose A is intravenously (IV) administered.</description>
    <arm_group_label>ABBV-323</arm_group_label>
    <other_name>Ravagalimab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABBV-323 Dose B</intervention_name>
    <description>ABBV-323 Dose B is administered subcutaneously (SC).</description>
    <arm_group_label>ABBV-323</arm_group_label>
    <other_name>Ravagalimab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must voluntarily sign and date an informed consent, approved by an
             independent ethics committee (IEC)/institutional review board (IRB), prior to the
             initiation of any screening or study-specific procedures.

          -  Diagnosis of UC for at least 3 months prior to Baseline. Appropriate documentation of
             biopsy results consistent with the diagnosis of UC in the assessment of the
             Investigator, must be available.

          -  Participant meets the following disease activity criteria: Active UC with an Adapted
             Mayo score of 5 to 9 points and endoscopic subscore of 2 to 3 (confirmed by central
             review).

          -  History of inadequate response, loss of response, or intolerance to one or more of the
             approved biologic therapies: infliximab, adalimumab, golimumab, vedolizumab, and/or
             tofacitinib (Note: If tofacitinib was received in a clinical trial, subject must have
             received open-label drug).

        Exclusion Criteria:

          -  Participant having an active, chronic, or recurrent infection that based on
             Investigator's clinical assessment makes the participant an unsuitable candidate for
             the study.

          -  Participant having any malignancy except for successfully treated non-metastatic
             cutaneous squamous cell or basal cell carcinoma or localized carcinoma in situ of the
             cervix.

          -  Participant with history of dysplasia of the gastrointestinal tract or evidence of
             dysplasia in any biopsy performed during the screening endoscopy other than completely
             removed low-grade dysplastic lesions.

          -  Laboratory values not meeting the following criteria : Serum aspartate transaminase
             (AST) and alanine transaminase (ALT) &lt;= 2* upper limit of normal (ULN); Total white
             blood cell (WBC) count &gt;= 3.0*10^9/L.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>847.283.8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Banner University Medical Cent /ID# 208392</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>TLC Clinical Research Inc /ID# 206626</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211-2091</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meridian Investigator Network /ID# 204646</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92648</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Orange County Institute of Gastroenterology and Endoscopy /ID# 207405</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691-6306</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>UC Davis Medical Center /ID# 209402</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago /ID# 207086</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chicago Association for Research and Education in Science (CARES) /ID# 208092</name>
      <address>
        <city>North Chicago</city>
        <state>Illinois</state>
        <zip>60064-3048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Affinity Clinical Research /ID# 206211</name>
      <address>
        <city>Oak Brook</city>
        <state>Illinois</state>
        <zip>60523</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Penn Presbyterian Medical Center /ID# 206826</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-2640</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Univ Med Ctr /ID# 204670</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-0011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Associates in Researc /ID# 204689</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hosp.-Toronto /ID# 206180</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Montreal General Hospital /ID# 204732</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chu de Nice-Hopital L'Archet Ii /Id# 208131</name>
      <address>
        <city>Nice CEDEX 3</city>
        <state>Alpes-Maritimes</state>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Beaujon /ID# 208129</name>
      <address>
        <city>Clichy</city>
        <state>Ile-de-France</state>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU NANCY - Hôpital Brabois Adultes /ID# 208133</name>
      <address>
        <city>Vandoeuvre les Nancy CEDEX</city>
        <state>Meurthe-et-Moselle</state>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Univ Hosp Schleswig-Holstein, Campus Kiel, Klinik furer Innere Medizin /ID# 207571</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charite Universitatsmedizin Berlin Campus Virchow Klinikum /ID# 207570</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Frankfurt /ID# 207569</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szegedi Tudomanyegyetem /ID# 221576</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universita di Catanzaro Magna Graecia /ID# 204546</name>
      <address>
        <city>Catanzaro</city>
        <state>Calabria</state>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complesso integrato Columbus /ID# 204549</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyungpook National Univ Hosp /ID# 209912</name>
      <address>
        <city>Daegu</city>
        <state>Daegu Gwang Yeogsi</state>
        <zip>41944</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Med Ctr /ID# 210447</name>
      <address>
        <city>Daegu</city>
        <state>Daegu Gwang Yeogsi</state>
        <zip>42415</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Maastricht Universitair Medisch Centrum /ID# 204428</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Franciscus Gasthuis &amp; Vlietland /ID# 206976</name>
      <address>
        <city>Rotterdam</city>
        <zip>3045 PM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Elisabeth Tweesteden Ziekenhuis /ID# 206272</name>
      <address>
        <city>Tilburg</city>
        <zip>5022 GC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Creu i Sant Pau /ID# 213259</name>
      <address>
        <city>Barcelona</city>
        <zip>08026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Maranon /ID# 204504</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz /ID# 210065</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth University Hos /ID# 206574</name>
      <address>
        <city>Glasgow</city>
        <state>Glasgow City</state>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital /ID# 206744</name>
      <address>
        <city>Belfast</city>
        <zip>BT12 6BA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. George's Healthcare NHS /ID# 206745</name>
      <address>
        <city>London</city>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>October 2, 2018</study_first_submitted>
  <study_first_submitted_qc>October 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2018</study_first_posted>
  <last_update_submitted>May 28, 2020</last_update_submitted>
  <last_update_submitted_qc>May 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ulcerative Colitis (UC)</keyword>
  <keyword>ABBV-323</keyword>
  <keyword>Ravagalimab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.htm</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

